REPORT TO THE LEGISLATURE
Pursuant to P.A. 119 of 2025
Article 2, Section 604
Hepatitis C Treatment Report

Sec. 604. Funds appropriated in part 1 for Hepatitis C treatment must be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used must be used only to purchase specialty medication for Hepatitis C treatment. Not later than February 15, the department shall issue a report for the previous fiscal year that includes all of the following:
(a) The total amount spent on specialty medication for the treatment of Hepatitis C.
(b) The number of prisoners who were treated for Hepatitis C.
(c) The amount of any rebates that were received from the purchase of specialty medication, and what, if any, outstanding rebates are expected to be received.
(d) The Hepatitis C status of all incoming prisoners and the number of prisoners who are reinfected while incarcerated and require retreatment for Hepatitis C.
(e) The number of those treated and released and then retreated upon reincarceration.

The total average monthly prisoner census for FY2025 was 32,614.

	# of Prisoners that started treatment during QTR	Total # of prisoners in treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR*	Total rebate received	Total rebate expected
1st QTR FY 2025	101	151	118	$1,732,079.49	($59,077.00)	
2nd QTR FY 2025	95	128	84	$1,401,906.75	($47,898.27)	
3rd QTR FY 2025	88	138	92	$1,437,783.40		$47,255.74
4th QTR FY 2025	103	142	56	$1,301,599.69		$34,751.53

*Total expenditures during quarter includes net costs of Hepatitis C medications and Hepatitis C lab testing charges.

Fibrosis Stage of Incoming, Treated Prisoners					
	Stage 0	Stage 1	Stage 2	Stage 3	Stage 4
Number of Prisoners	91	183	60	26	27